Editas Medicine (EDIT) Reports Q1 Loss of $0.60

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. MRK
8. LVS
9. CSX
10. LRCX

Go back to Editas Medicine (EDIT) Reports Q1 Loss of $0.60

Editas Medicine Announces First Quarter 2019 Results and Update

May 7, 2019 4:03 PM EDT

- Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer -

- EDIT-101 (AGN-151587) for LCA10 on track for first patient dosing in second half of 2019 -

- Initiated IND-enabling activities for potentially best-in-class medicine for sickle cell disease and beta-thalassemia -

- $342 million of cash, cash equivalents, and marketable securities as of March 31, 2019 -

CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq:... More